Patient-centric dose equivalency pilot study of incobotulinumtoxin a (xeomin) vs. abobotulinumtoxin a (dysport) in the treatment of glabellar frown lines: Bank J et al.

Abstract: Aim: Incobotulinumtoxin A (xeomin) has been proposed as an alternative to abobotulinumtoxinA (dysport) and onabotulinumtoxin A (Botox) in the treatment of glabellar frown lines. A recent
study is comparing abobotulinumtoxin A and onabotulinumtoxin A revealed equivalent efificacy with a dose conversion ratio of 2.5:1. …

Plast Aesthet Res || Vol 2 || Issue 1 || Jan 15, 2015
 
Autoren:
Jonathan Bank   1,
Nicole A. Phillips   2,
Laurie A. Casas   1
 
 
 
Autoren-Details:
1   Department of Surgery, Section of Plastic and Reconstructive Surgery, University of Chicago Medical Center, Chicago, IL 60026, USA.
2  Department of Surgery, Division of Plastic Surgery, Brigham and Women’s Hospital, Boston, MA 02115, USA.
Address for correspondence:
 Dr. Laurie A. Casas, Department of Surgery, Section of Plastic and Reconstructive Surgery, University ofChicago Medical Center, Chicago, IL 60026, USA. E-mail: lcasas@casas.md